Insider Buying: Clarity Pharmaceuticals Ltd (ASX:CU6) Insider Buys A$35,706.91 in Stock

Clarity Pharmaceuticals Ltd (ASX:CU6) insider Robert Thomas bought 8,333 shares of Clarity Pharmaceuticals stock in a transaction dated Monday, May 20th. The stock was acquired at an average price of A$4.29 ($2.86) per share, for a total transaction of A$35,706.91 ($23,804.60).

Robert Thomas also recently made the following trade(s):

• On Monday, April 29th, Robert Thomas 16,667 shares of Clarity Pharmaceuticals stock.

Clarity Pharmaceuticals Price Performance

Clarity Pharmaceuticals Company Profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.